The effect of olanzapine on lipid profiles in humans: a time and dose response meta-analysis of randomized controlled trials
Olanzapine treatment is associated with a distinct dyslipidemic profile, characterized by increased TG, TC, and LDL-C and reduced HDL-C, particularly at higher doses and during early treatment. These findings underscore the need for proactive lipid monitoring and cardiovascular risk assessment, especially in patients with low baseline BMI, who appear more susceptible to rapid lipid alterations, and in those with existing metabolic risk factors or multiple cardiometabolic comorbidities.
Authors
- Parmida Jamilian (ORCID: https://orcid.org/0000-0002-6087-6448)
- Fang Zhou (ORCID: https://orcid.org/0000-0002-7775-069X)
- Mohammad Safargar
- Shuang Liu (ORCID: https://orcid.org/0000-0003-2347-413X)
- Kousalya Prabahar (ORCID: https://orcid.org/0000-0003-3571-492X)
Institutions
- Zhejiang Chinese Medical University (CN)
- Tabriz University of Medical Sciences (IR)
- Zhejiang Hospital (CN)
- Zhejiang Provincial People's Hospital (CN)
- Hangzhou Medical College (CN)
- Keele University (GB)
- University of Tabuk (SA)
Publication Details
- Journal
- BMC Cardiovascular Disorders
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1186/s12872-025-05476-z
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00